Amicus Therapeutics, Inc.
FOLDDelisted Apr 27, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178879
Amicus Therapeutics, Inc. was delisted on Apr 27, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 298 institutions reported holding it in 13F filings for Q1 2026, worth $4.81B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Amicus Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 226 | 3 | 216 | −7 |
| Shares | 297.7M | 14.8K | 307.3M | +9.58M (+3.2%) |
| Value | $3.30B | $164.5K | $3.86B | +$557.0M (+16.9%) |
3 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (25)
Institutions that held Amicus Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (32)
Institutions that held Amicus Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
Not filed for Q2 2023 yet (3)
Institutions that held Amicus Therapeutics, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Zebra Capital Management LLC | 12,352 | $137.0K |
| Pathway Financial Advisers, LLC | 2,325 | $25.8K |
| Harvest Group Wealth Management, LLC | 156 | $1.73K |